Listen to what this leading medical oncologist has to say about actionable biomarkers… Dr Balazs Halmos said, “Nowadays, we just need to make sure that we leave no drivers behind. By now, we have 8 different biomarkers that can be validated biomarkers for the selection of targeted therapies, either FDA-approved or very exciting agents in clinical studies.”

“Both molecular testing and tissue as well as ctDNA is now available to make sure that these drivers are being tested for,” added the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Einstein Center for Cancer Care. The Guardant360® test is done using circulating tumor DNA (ctDNA). The turnaround time of approximately seven days for this blood test makes quick treatment decisions a reality. Visit us @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. Guardant360®. Test. Take Action.